A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

Status:
RECRUITING

Trial end date:
2027-02-09

Target enrollment:

Participant gender:

The purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).

PHASE2

Amgen